Liver Fluke Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Market Is Segmented by Drug Type (Albendazole, Praziquantel, Triclabendazole, Nitazoxanide, and Other Drug Types), Application (Human, Cattle, and Other Applications), and Geography.

Market Snapshot

Liver Fluke Treatment Market 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The liver fluke treatment market is expected to register a CAGR of 4.2% during the forecast period. Liver flukes are parasites that can cause a disease called fascioliasis in humans, cattle, and sheep. The liver fluke infection is caused by worms such as Fasciola hepatica and Fasciola gigantica. Infections in humans usually occur after eating contaminated raw or undercooked freshwater fish or watercress. Liver fluke infected individuals mostly don’t show any symptoms, and sometimes symptoms arise related to the biliary system. In rare cases, long-term complications can also develop. Some of the signs of liver fluke infection are abdominal pain, malaise, diarrhea, nausea and vomiting, fever, and decreased appetite and weight loss.

According to the Centers for Disease Control and Prevention (CDC), fascioliasis occurs in many areas of the world, a common liver fluke of sheep and cattle. Moreover, fascioliasis is more common and widespread in animals than in people. Even so, the number of infected people is thought to exceed two million worldwide. In addition, as per the study published in The American Journal of Tropical Medicine and Hygiene, estimates the prevalence of 2.6 million infected and 91 million at risk of developing an infection, worldwide.

Increasing cases of liver fluke infection in humans and animals and growing awareness of liver fluke infections among the population are the key driving factors in the liver fluke treatment market.

Scope of the Report

Liver flukes are parasites that can cause diseases in humans and some animals. Liver fluke treatment market is segmented by drug type, application, and geography.

By Drug Type
Other Drugs
By Application
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Triclabendazole Segment is Expected to Hold a Major Market Share in the Liver Fluke Treatment Market

  • Triclabendazole is a benzimidazole compound used routinely in veterinary practice for the treatment of fascioliasis. In the year 1997, after clinical trials using triclabendazole for the treatment of fascioliasis, the World Health Organization (WHO), recommended that the drug be placed on the Essential Drugs List.
  • According to the World Health Organization (WHO), estimates worldwide at least 2.4 million people are infected with fascioliasis in more than 70 countries, with several million at risk. In addition, infection is present in domestic animals in almost all countries where cattle and sheep are reared.
  • The triclabendazole segment holds a significant market share in the liver fluke treatment market and is anticipated to show a similar trend over the forecast period.
  • Moreover, triclabendazole is highly effective compared to other drugs, and it is considered first-line therapy against liver fluke infections by the Center for Disease Control (CDC) and the World Health Organization (WHO).
liver fluke trend 1.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global liver fluke treatment market due to the increasing prevalence of Fasciola hepatica infections in cattle and sheep in this region. As per the study published in The American Journal of Tropical Medicine and Hygiene, estimates that veterinary disease is prevalent in multiple areas in the United States and maybe expanding. Moreover, a high prevalence of Fasciola hepatica infections in cattle in California and in some areas, 90% of adult cattle are infected with Fasciola hepatica. Furthermore, an increase in research and development for liver fluke treatment is also fueling the overall regional market's growth.

Liver Fluke Treatment Market 2

Competitive Landscape

The liver fluke treatment market is competitive and consists of several major players. Some of the leading market players include Novartis AG, GlaxoSmithKline Plc, Bayer AG (Bayer Animal Health), Endo International Plc (Par Pharmaceutical), Romark Laboratories, L.C, Zoetis Inc, Merck & Co. Inc, Lupin Pharmaceuticals Inc, and Schering-Plough Corporation, among others.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Fascioliasis Infection in Humans and Cattle

      2. 4.2.2 Raising Awareness on Liver Fluke, Fascioliasis Infection Among the People by Government Organizations

      3. 4.2.3 Increasing Research and Development for Liver Fluke Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 Requirement of Long Treatment Cycles for Liver Fluke Infection

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Albendazole

      2. 5.1.2 Praziquantel

      3. 5.1.3 Triclabendazole

      4. 5.1.4 Nitazoxanide

      5. 5.1.5 Other Drugs

    2. 5.2 By Application

      1. 5.2.1 Human

      2. 5.2.2 Cattle

      3. 5.2.3 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 GlaxoSmithKline Plc

      3. 6.1.3 Bayer AG (Bayer Animal Health)

      4. 6.1.4 Endo International Plc (Par Pharmaceutical)

      5. 6.1.5 Romark Laboratories LC

      6. 6.1.6 Zoetis Inc

      7. 6.1.7 Merck & Co. Inc

      8. 6.1.8 Lupin Pharmaceuticals Inc

      9. 6.1.9 Schering-Plough Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Liver Fluke Treatment Market market is studied from 2018 - 2026.

The Liver Fluke Treatment Market is growing at a CAGR of 4.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Novartis AG, GlaxoSmithKline Plc, Bayer AG (Bayer Animal Health), Endo International Plc (Par Pharmaceutical), Romark Laboratories, L.C. are the major companies operating in Liver Fluke Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!